Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (5): 720-725    DOI: 10.31083/j.ejgo.2020.05.5453
Original Research Previous articles | Next articles
Simultaneous Integrated Intensity Modulated Radiotherapy Boost for Gynecological Cancer when Brachytherapy is not an Option
Eda Kucuktulu1, *(), Ahmet Fatih Yurekli2
1SBU Trabzon Kanuni Training and Research Hospital. Dept of Radiation Oncology. Trabzon, Turkey
2Gulhane Training and Research Hospital. Department of Radiation Oncology Ankara, Turkey
Download:  PDF(1250KB)  ( 181 ) Full text   ( 14 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: Brachytherapy (BT) lowers the risk of recurrence and improves the survival rate when used after external beam radiotherapy (EBRT) in cervical cancers. In endometrial cancers vaginal cuff BT lowers the risk of vaginal recurrence. New treatment methods have been investigated since BT is not an option for some patients mainly due to difficulties in the placement of BT applicators. Simultaneous integrated boost (SIB) has recently been investigated as an alternative modality in patients when BT is not suitable after EBRT. Materials and Methods: Five patients with cervical cancer and four patients with endometrial cancer were treated with SIB IMRT. In the five cervical cancer patients SIB treatment volumes were given a 74 Gy dose in 2,54 Gy fractions and common iliac and presacral lymphatic lymph node volumes were given 50,4 Gy in 1,74 Gy fractions. In the four patients with endometrial cancer the vagina and paravaginal-parametrial regions received a dose of 60 Gy in 2,3 Gy fractions using a 10 mm margin while a dose of 45 Gy in 1,73 fractions was administered to common iliac, external-internal iliac and obturator lymph nodes. Results: The five patients with the diagnosis of inoperable cervical cancer remained in complete remission (CR) through a median follow-up of 45 months (18-78 months) with a local control (LC) rate of 100%. Acute side effects were seen in 2 patients with cervical cancer and in 2 patients with endometrial cancer. Late side effects were observed in one patient in each of the cervical and endometrial cancer groups. Discussion: SIB-IMRT is an alternative treatment option for patients with cervical or endometrial cancer. Although this pilot study describes a limited number of patients it does suggest long term favorable results can be obtained with this method.
Key words:  Cervical cancer      Endometrial cancer      SIB      IMRT     
Submitted:  26 December 2019      Accepted:  23 July 2020      Published:  15 October 2020     
*Corresponding Author(s):  EDA KUCUKTULU     E-mail:  ekucuktulu@yahoo.com

Cite this article: 

Eda Kucuktulu, Ahmet Fatih Yurekli. Simultaneous Integrated Intensity Modulated Radiotherapy Boost for Gynecological Cancer when Brachytherapy is not an Option. European Journal of Gynaecological Oncology, 2020, 41(5): 720-725.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.05.5453     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I5/720

[1] Ikuji Shimazaki, Yasunori Hashiguchi, Makoto Yamauchi, Mari Kasai, Takeshi Fukuda, Tomoyuki Ichimura, Tomoyo Yasui, Toshiyuki Sumi. Secondary small cell vaginal cancer after operative therapy for endometrial cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 821-823.
[2] Yu Hui Lim, Sheow Lei Lim, Linda Xiao Hui Lin, Lay Tin Soh, Hoon Seng Khoo Tan, Richard Ming Chert Yeo, Timothy Yong Kuei Lim. Sequential Chemoradiation versus Radiation for the Adjuvant Treatment of Stage III Endometrioid Adenocarcinoma of the Uterus[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 705-712.
[3] Wook Youn Kim, Shin Hee Seo, Seung-Hyuk Shim, Jin Hee Park, Hyung Kyu Park, Kyeong A So, Tae Jin Kim, Sun Joo Lee. Correlation of immunohistochemistry and silver in situ hybridization for the assessment of c-MET in uterine cervical cancer patients treated with radical hysterectomy[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 745-752.
[4] John P. Micha, Howard D. Epstein, Michael C. Roossin, Randy Bohart, Mark A. Rettenmaier, Bram H. Goldstein. Neoadjuvant chemotherapy, radical hysterectomy and chemoradiation for stage iva cervical carcinoma[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 797-801.
[5] Juan Xu, Qingqing Tan, Ting Li. USP22 promotes the expression of GLUT1 and HK2 to facilitate growth and glycolysis in cervical cancer cells[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 790-796.
[6] Yan qin Zhang, Di Wu, Meng qi Deng, Xiang yu Chang, Jin wei Miao, Yu mei Wu. Individual management of cervical cancer during pregnancy[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 833-837.
[7] Michelle F. Benoit, Kristy K. Ward. Uterine Cancer Normogram to Predict Lymph Node Metastasis: Comparison to the Mayo Algorithm and an External Validation of a Model in a North American Population[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 681-684.
[8] Yi-fan Luo, Li-xiang Ren, Ming-yan Jiang, Yang Chu. A systematic review and meta-analysis on the effects of metformin on survival outcomes and risk in women with cervical cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 504-507.
[9] Liman Yang, Jing Jin, Juhong Liu. Correlation of MMP2-C1306T (rs243865) and MMP7-181A/G (rs11568818) with cervical cancer: a meta-analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 508-512.
[10] Yusuf Cakmak, Tufan Oge. The effect of age on prediction of concurrent endometrial cancer in patients with atypical endometrial hyperplasia[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 531-535.
[11] Panteleimon Mnimatidis, Abraham Pouliakis, George Valasoulis, George Michail, Aris Spathis, Christine Cottaridi, Niki Margari, Maria Kyrgiou, Maria Nasioutziki, Alexandros Daponte, Konstantinos Dinas, Evangelos Paraskevaidis, Ioannis Panayiotides, Dimitrios-Dionysios Koutsouris. Multicentric assessment of cervical HPV infection co-factors in a large cohort of Greek women[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 545-555.
[12] Fengmei Wang , Huachun Luo , Huihua Cheng, Huijuan Huang , Zhichao Fu. Is 3D printing-gided three-dimensional brachytherapy suitable for cervical cancer: from one single research institute?[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 591-597.
[13] Di Wu, Jirui Zhang, Chengxi Yang. Effect of letrozole combined with testosterone on the proliferation and apoptosis of endometrial carcinoma cells[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 604-608.
[14] Hiroshi Yoshida, Megumi Yamamoto, Hiroyuki Shigeta. Successful treatment of uterine cervical carcinoma with extensive vaginal lesions using laparoscopic surgery: A case report[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 629-633.
[15] Hikari Unno, Seiji Mabuchi, Isao Arai, Tomoko Wakasa, Seiichi Yamamasu. Development of lymphangiosarcoma after pelvic radiation therapy for uterine cervical cancer: A case report and literature review[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 326-331.
[1] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31 -46 .
[2] B. Soltész, J. Lukács, A. Penyige, R. Póka, B. Nagy. Determination of miR-193b rs30236 single nucleotide polymorphism in ovarian cancer patients[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 547 -550 .
[3] Y. Li, C. Li, N. Li, L. Jiang, W. Yang, Y. Wang, B. Wu, C. Shi, Z. Zhu. RNAi silenced NUP88 gene suppresses growth and invasiveness of human breast cancer cell line MCF-7[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 634 -639 .
[4] M. Pakiž, L. Lukman, N. Kozar. Patients' and physicians' expectations differ significantly during the follow-up period after completion of primary treatment of gynecological or breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 781 -786 .
[5] T. Tomimatsu, S. Mabuchi, T. Tsuboyama, Y. Hori, S. Sekine, T. Kimura. Malignant transformation of uterine leiomyoma: suggested by clinical, imaging, histological, and genetic findings[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 879 -882 .
[6] T. Ueno, H. Yabushita, K. Iwasaki, A. Wakatsuki. Role of adiponectin and leptin in non-diabetic, non-obese patients with endometrial cancer[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 199 -204 .
[7] P. Pimsi, W. Santimaleeworagun, S. Therasakvichya, N. Saengsukkasemsak, A. Laocharoenkeat. The incidence and risk factors of severe neutropenia and febrile neutropenia due to chemotherapy among gynecologic cancer patients in Thailand[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 242 -246 .
[8] F. Lai-Tiong. Dermatomyositis revealing a 18-year breast cancer recurrence[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 292 -293 .
[9] M.F. Benoit, K.A. O'Hanlan, M.S. Sten, C.L. Kosnik, D.M. Struck, M.S. O'Holleran, J. Cuff, D.M. Halliday, E.A. Kent. Incidental appendectomy at the time of gynecologic surgery[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 386 -389 .
[10] E. Yilmaz, E. I. Coskun, C. Koc, N. Sahin, B. Isik, B. Ciplak. Isolated recurrence of early-stage cervical cancer in the abdominal wall with suboptimal surgery[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 485 -487 .